Pharmaceutical - Pharmaceutical, Roche

Filter

Current filters:

PharmaceuticalRoche

Popular Filters

1 to 25 of 331 results

Pharmacyclics and Roche research Imbruvica and Gazyva

Pharmacyclics and Roche research Imbruvica and Gazyva

17-10-2014

USA-based biopharma company Pharmacyclics has entered into a master clinical drug supply agreement with…

GazyvaImbruvicaOncologyPharmaceuticalPharmacyclicsResearchRocheUSA

Roche posts solid sales performance for first nine months of 2014

Roche posts solid sales performance for first nine months of 2014

16-10-2014

Swiss pharma major Roche this morning released its financials for the first nine months of 2014, showing…

Economy of SwitzerlandFinancialPharmaceuticalRocheSwitzerlandtrastuzumab

Roche signs deal with DKSH to expand access across Asia

Roche signs deal with DKSH to expand access across Asia

15-10-2014

Switzerland-based market expansion services provider DKSH has signed an agreement with Swiss pharma major…

AsiaAsia-PacificDKSHManagementPharmaceuticalRocheRoche Thailand LimitedSwitzerland

Roche could lose its dominant market share in breast cancer, says IMS report

Roche could lose its dominant market share in breast cancer, says IMS report

03-10-2014

Biosimilars and new generation agents will end the market dominance of established breast cancer drugs,…

AstraZenecaGlobalHerceptinMarkets & MarketingNovartisOncologyPharmaceuticalRochetamoxifen

Data uncertainties mean NICE does not recommend Roche leukemia drug

Data uncertainties mean NICE does not recommend Roche leukemia drug

03-10-2014

In yet another rejection of the company’s cancer drugs, the UK drugs watchdog, the National Institute…

GazyvaroOncologyPharmaceuticalPricingRegulationRocheUK

Report: HER2-positive breast cancer market could treble in USA by 2023

Report: HER2-positive breast cancer market could treble in USA by 2023

02-10-2014

The US treatment market for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer…

HerceptinMarkets & MarketingOncologyPharmaceuticalRocheUSA

ESMO 2014: Roche's cobimetinib and Perjeta; Specialised Therapeutics Australia's anamorelin

ESMO 2014: Roche's cobimetinib and Perjeta; Specialised Therapeutics Australia's anamorelin

29-09-2014

Swiss drug major Roche presented positive results from a Phase III study of cobimetinib plus Zelboraf…

anamorelincobimetinibHelsinnOncologyPerjetaPharmaceuticalResearchRocheSpainSpecialised Therapeutics Australia

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

26-09-2014

The non-Hodgkin lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia,…

AdcetrisAustraliaChinaGazyvaroIndiaJapanMarkets & MarketingOncologyPharmaceuticalRocheTakeda Pharmaceutical

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

Compromised vials of Roche's MabThera found in Germany

Compromised vials of Roche's MabThera found in Germany

15-09-2014

Swiss drug major Roche has said that compromised vials of its arthritis and cancer drug MabThera had…

GermanyHerceptinLegalMabTheraOncologyPharmaceuticalProductionRegulationRoche

Roche’s RoActemra gains EU approval for use in early RA

Roche’s RoActemra gains EU approval for use in early RA

08-09-2014

The European Commission has approved Swiss pharma major Roche’s RoActemra (tocilizumab) for use in…

ActemraAnti-Arthritics/RheumaticsEuropeInterleukin 6PharmaceuticalRegulationRoActemraRoche

Chugai launches ALK inhibitor Alecensa in Japan

Chugai launches ALK inhibitor Alecensa in Japan

07-09-2014

Japanese drugmaker Chugai Pharmaceutical said on Friday that it has launched the ALK inhibitor Alecensa…

AlecensaalectinibChugai PharmaceuticalJapanMarkets & MarketingOncologyPharmaceuticalRoche

Chugai and Roche amend business arrangements on out-licensing

Chugai and Roche amend business arrangements on out-licensing

31-08-2014

Japanese drugmaker Chugai has amended the business arrangements with its majority (62%) share-owner Swiss…

Asia-PacificChugai PharmaceuticalEuropeLicensingPharmaceuticalRoche

Roche makes another acquisition, paying $8.3 billion for InterMune

Roche makes another acquisition, paying $8.3 billion for InterMune

25-08-2014

Announcing its fourth acquisition this year, Swiss pharma major Roche said on Sunday that it has entered…

EsbrietInterMuneMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryRoche

Roche said to be eyeing full control of Chugai

Roche said to be eyeing full control of Chugai

18-08-2014

Although the Swiss drug major has not issued a confirmation, media reports say Roche is close to acquiring…

Business FinanceChugai PharmaceuticalChugai Pharmaceutical Co.Chugai PharmaceuticalsHoffmann-La RocheInvestmentMergers & AcquisitionsPharmaceuticalRoche

Roche’s Avastin gets FDA approval for use with chemotherapy in cervical cancer

Roche’s Avastin gets FDA approval for use with chemotherapy in cervical cancer

15-08-2014

Swiss drug major Roche has received approval from the US Food and Drug Administration for its drug Avastin…

AvastinCervical cancerOncologyPharmaceuticalRegulationRocheSwitzerland

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

13-08-2014

“The National Institute for Health and Care Excellence’s recent rejection of Kadcyla, Roche’s latest…

KadcylaOncologyPharmaceuticalPricingRegulationRocheUK

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

NICE disappointed by Roche’s decision on Kadcyla pricing

NICE disappointed by Roche’s decision on Kadcyla pricing

08-08-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) said this morning…

Breast cancerCancerKadcylaNational Health ServiceOncologyPharmaceuticalPricingRegulationRocheUK

Patient involvement pilot for orphan drugs launches in Canada

Patient involvement pilot for orphan drugs launches in Canada

07-08-2014

Canada’s Minister of Health, Rona Ambrose, says that the government has launched a pilot project targeting…

CanadaHealth CanadaPharmaceuticalRare diseasesRegulationResearchRocheTreatment of chronic lymphocytic leukemia

NICE comes back with different views on Tarceva and Iressa for NSCLC

NICE comes back with different views on Tarceva and Iressa for NSCLC

07-08-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is consulting again…

AstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer

EU approves Roche’s Avastin for platinum-resistant recurrent ovarian cancer

06-08-2014

The European Commission has approved the use of Swiss pharma major Roche’s blockbuster cancer drug…

AvastinEuropeOncologyPharmaceuticalRegulationRocheTreatment for women with recurrent ovarian cancer

1 to 25 of 331 results

Back to top